As of June 30, 2026, NIKA PHARMACEUTICALS INC. carries a market capitalization of 806.33M, placing it among publicly traded companies globally. Its enterprise value stands at 806.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 806.33M |
| Enterprise Value | 806.33M |
As of June 30, 2026, NIKA PHARMACEUTICALS INC. has 1.05B shares outstanding.
| Shares Outstanding | 1.05B |
These figures are as of June 30, 2026.
| PB Ratio | -2,427.39 |
| P/TBV Ratio | -2,427.39 |
| P/FCF Ratio | -11,643.39 |
| P/OCF Ratio | -11,643.39 |
As of June 30, 2026, NIKA PHARMACEUTICALS INC. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.03 |
| Quick Ratio | 0.01 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -376.14, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -376.14 |
As of the close on October 28, 2026, NIKA PHARMACEUTICALS INC.'s stock has gained approximately 16.59% over the past 52 weeks.
| 52-Week Price Change | 16.59% |
| 50-Day Moving Average | 0.43 |
Over the twelve months ended June 30, 2026, NIKA PHARMACEUTICALS INC. generated - - in revenue and converted that into -78,141.00 in net income, yielding earnings per share of 0.00. EBITDA reached -78,141.00, while operating income came in at -78,123.00.
| Operating Income | -78,123.00 |
| Pretax Income | -78,141.00 |
| Net Income | -78,141.00 |
| EBITDA | -78,141.00 |
| EBIT | -78,141.00 |
These figures are as of June 30, 2026. Total book value stands at -332,182.00, with working capital of -330,682.00 providing operational flexibility.
| Cash & Cash Equivalents | 2,932.00 |
| Net Debt | -2,932.00 |
| Equity (Book Value) | -332,182.00 |
| Working Capital | -330,682.00 |
NIKA PHARMACEUTICALS INC. produced -69,144.00 in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -69,144.00 |
| Free Cash Flow | -69,144.00 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.01, meaning NIKA PHARMACEUTICALS INC. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.01 |
| FCF Yield | -0.01 |
As of June 30, 2026, NIKA PHARMACEUTICALS INC. has an Altman Z-Score of 81.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 81.92 |